Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Arcturus Therapeutics Holdings Inc. (ARCT)

$5.53 -4.49% NASDAQ: ARCT · 15-min delayed
  • SAN DIEGO, California
  • Public · NASDAQ: ARCT
  • 111 employees
$207.5MMarket cap
$82.0MRevenue · FY2025
-$65.8MNet income
111Employees
ARCTNASDAQ
2013IPO

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$82.0M
Net income
-$65.8M
Total assets
$271.1M
Market cap
$207.5M
Operating margin
-93.0%
Net margin
-80.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$82.0M
Operating expenses
$158.3M
Operating income
-$76.3M
Net income
-$65.8M
EPS (basic)
$-2.40
EPS (diluted)
$-2.40

Balance sheet

Total assets
$271.1M
Current assets
$241.4M
Total liabilities
$57.2M
Current liabilities
$36.4M
Shareholders’ equity
$214.0M

Cash flow

Operating cash flow
-$74.3M
Investing cash flow
-$230.0K
Financing cash flow
$13.4M
Net cash flow
-$61.1M

Statements via Polygon.io (SEC filings)

NASDAQ: ARCT
$5.53 -4.49%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$5.53 $23.16

52-week range

Market cap
$207.5M
EPS (diluted)
$-2.4
Shares outstanding
37.5M
Open
Day range
Prev close
Volume
IPO date
May 22, 2013

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price

  • Reported a net loss of $65.8M in FY2025.
  • Revenue grew 564% from FY2021 to FY2025.
  • Trading 76% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Arcturus Therapeutics Holdings Inc..

Write a review
Newsroom

News about Arcturus Therapeutics Holdings Inc.

News & sentiment via Polygon.io

FAQ

Arcturus Therapeutics Holdings Inc.: frequently asked questions

Is Arcturus Therapeutics Holdings Inc. an American company?

Arcturus Therapeutics Holdings Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Arcturus Therapeutics Holdings Inc. headquartered?

Arcturus Therapeutics Holdings Inc. is headquartered in San Diego, California, United States.

Is Arcturus Therapeutics Holdings Inc. publicly traded?

Yes — Arcturus Therapeutics Holdings Inc. is a publicly traded company. Its stock trades under the ticker symbol ARCT on the NASDAQ.

What does Arcturus Therapeutics Holdings Inc. do?

Arcturus Therapeutics Holdings Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →